oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System
Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Medical Research Institute, College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells Hospital, Dundee, UK.
Department of Intensive and Perioperative Care, Skåne University Hospital, Lund, Sweden.
Department of Surgical Sciences, Otorhinolaryngology, and Head & Neck Surgery, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2014 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 96, no 4, 477-481 p.Article, review/survey (Refereed) Published
Abstract [en]

Angioedema is a potentially life-threatening adverse reaction to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicenter recruitment of patients are needed. To reduce patient heterogeneity, we have standardized the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.

Place, publisher, year, edition, pages
Nature Publishing Group, 2014. Vol. 96, no 4, 477-481 p.
National Category
Pharmacology and Toxicology
Research subject
Pharmaceutical Pharmacology
Identifiers
URN: urn:nbn:se:oru:diva-38516DOI: 10.1038/clpt.2014.138ISI: 000342675400026PubMedID: 24960520Scopus ID: 2-s2.0-84905624986OAI: oai:DiVA.org:oru-38516DiVA: diva2:762265
Funder
Swedish Heart Lung FoundationSwedish Research Council
Note

Funding Agencies:

European Union 602108

Clinical Research Support (ALF) at Uppsala University

UK Department of Health (National Health Service chair of Pharmacogenetics)

Medical Research Council Center for Drug Safety Science

Serious Adverse Event Consortium

National Institute for Health Research senior investigator

Available from: 2014-11-11 Created: 2014-11-11 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Hugosson, Svante
By organisation
School of Medicine, Örebro University, SwedenÖrebro University Hospital
In the same journal
Clinical Pharmacology and Therapeutics
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 32 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf